• Patrick Davey and Kyriacos Alexandrou.
• Northampton General Hospital, Cliftonville, Northampton NN1 5BD, UK.
• Int. J. Clin. Pract. 2022 Jan 1; 2022: 29768112976811.

BackgroundCardiovascular disease (CVD) is a common comorbidity in patients with prostate cancer. In this review, we summarize the published literature on the association of cardiovascular risk with androgen deprivation therapy (ADT) treatment and explore the potential differences between the gonadotropin-releasing hormone (GnRH) agonists and antagonists and the molecular mechanisms that may be involved. We also provide a practical outlook on the identification of underlying CV risk and explore the different stratification tools available.ResultsWhile not definitive, the current evidence suggests that GnRH antagonists may be associated with lower rates of certain CV events vs agonists, particularly in patients with preexisting CVD. Risk reduction strategies such as lifestyle advice, consideration of ADT modality, and comedications may help to reduce CV risk factors and improve outcomes in prostate cancer patients receiving ADT.ConclusionsGiven all the data that is currently available, identification of baseline CV risk factors may be key to risk mitigation in patients with prostate cancer receiving ADT.Copyright © 2022 Patrick Davey and Kyriacos Alexandrou.

12 keywords...

hide…